Commercial

Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’

BioSpace

Analysts will be watching as a generic version of semaglutide--marketed by Novo Nordisk as Wegovy for weight loss--launches in Canada as a test case for future price erosion in the U.S.

Metabolic & GLP-1

Read full story

pharminent April 29, 2026 (Last updated: April 29, 2026)

BioSpace

Analysts will be watching as a generic version of semaglutide–marketed by Novo Nordisk as Wegovy for weight loss–launches in Canada as a test case for future price erosion in the U.S.

Metabolic & GLP-1

Read full story

Related Stories

Lilly UK recruits ex-England cricketer as obesity champion

A year after Vertex’s big launch, pain drug research faces a pivotal moment

Daiichi takes $850M charge, axes facility investment as ADC demand forecast falls

You May Have Missed

Eli Lilly to buy trio of vaccine developers in $3.8bn outlay

Arthrosi drug trial in gout delivers for new owner Sobi

Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study

Pierre Fabre’s Braftovi gains CHMP positive opinion for mCRC